

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board announces the following changes with effect from 8 July 2025:

- (1) Dr. Cheng Faat Ting Gary ("**Dr. Cheng**") has tendered his resignation as an independent non-executive director of the Company ("**INED**") and ceased to act as the chairman of each of the audit committee and remuneration committee of the Company;
- (2) Ms. Wang Yachun ("**Ms. Wang**") has been appointed as the chairman of the remuneration committee of the Company; and
- (3) Mr. Tsui Wing Tak ("**Mr. Tsui**") has been appointed as the chairman of the audit committee of the Company.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") hereby announces that Dr. Cheng has tendered his resignation as an INED and ceased to act as the chairman of each of the audit committee (the "**Audit Committee**") and the remuneration committee (the "**Remuneration Committee**") of the Company with effect from 8 July 2025, as he intended to devote more time to his other business and personal commitments.

Dr. Cheng has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude for the valuable contribution that Dr. Cheng has made to the Company during his tenure of service.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board further announces that with effect from 8 July 2025, Ms. Wang, currently is a member of the remuneration committee, has been appointed as the chairman of the remuneration committee in place of Dr. Cheng following his resignation.

Mr. Tsui, currently is a member of the audit committee, has been appointed as the chairman of the audit committee in place of Dr. Cheng following his resignation with effect from 8 July 2025.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 8 July 2025

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Ms. Zhang Yujing; the non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the independent non-executive directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.